
SLU-PP-332 is a synthetic small-molecule compound characterized in laboratory research as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ). In controlled experimental systems, activation of PPARδ is examined for its role in regulating gene networks associated with fatty acid oxidation, mitochondrial biogenesis, and cellular energy utilization.
Preclinical studies—including in vitro assays and animal models—evaluate how PPARδ-dependent transcriptional modulation influences lipid metabolism pathways, oxidative capacity markers, and mitochondrial function. Research applications frequently focus on endurance-associated signaling, metabolic flexibility, and transcriptional programs governing energy homeostasis under defined laboratory conditions. These model systems provide structured environments for investigating nuclear receptor–mediated metabolic regulation without implying human application.
All Hanobi® research compounds are manufactured under rigorous quality control standards and sourced from independently vetted, accredited suppliers. Each batch undergoes analytical verification to confirm identity and purity, ensuring consistency, traceability, and compliance with federal and state regulations governing research-use materials.
Capsules are supplied solely as inert containers for the dry transport, storage, and handling of laboratory research materials. They are not dosage forms and are not intended for ingestion or administration. They must not be used as drug delivery systems, consumed, or administered in any manner.
Not for use in humans or animals. Not for diagnostic or therapeutic purposes.
Narkar VA et al., Cell, 2008;134(3):405–415
Fan W et al., Journal of Biological Chemistry, 2004;279(7):5241–5248
Billon C et al., Cell Metabolism, 2022;34(1):69–84